Agoracom Blog

Revolutionizing Healthcare: AI Scanner Promises Faster Assessments and Enhanced Safety

Posted by Brittany McNabb at 8:20 PM on Thursday, September 14th, 2023


In the realm of healthcare technology, a remarkable innovation is poised to transform patient care and safety. Predictmedix AI, a Toronto-based health tech company, has unveiled an AI-powered scanner that not only accelerates assessment times in hospitals but also plays a pivotal role in maintaining a drug-free environment by detecting cannabis. Let’s delve into how this groundbreaking technology is set to reshape healthcare practices.

Swift Assessments for Faster Care

Getting all the vital signs needed for patient diagnosis has traditionally been a time-consuming process. Predictmedix AI’s Safe Entry Station, an AI-powered scanner, is changing the game. This device can swiftly monitor vital signs, including heart rate and respiration rates, and even detect alcohol or cannabis intoxication. What sets it apart is its ability to provide this data in a matter of seconds, without invasive procedures or blood samples.

Redefining Triage Efficiency

For patients who spend hours in emergency rooms, a technology capable of significantly reducing triage times is a game-changer. Predictmedix AI’s scanner can shorten this process from up to an hour to less than 20 seconds. It achieves this by capturing vitals in a completely non-invasive, contactless manner. The results seamlessly integrate into the hospital’s medical system, enhancing overall efficiency.

Enhanced Safety with Cannabis Detection

Beyond rapid assessments, the AI scanner has an additional, unique capability: it can detect cannabis on individuals entering healthcare facilities. In regions where cannabis use is regulated or prohibited within healthcare premises, this feature ensures compliance and enhances security.

How It Works

The Safe Entry Station is equipped with multi-spectral cameras that analyze different wavelengths and a host of sensors. An edge computing unit, a powerful computer, processes this data on-site. Proprietary technology allows these cameras to analyze subtle changes in blood flow patterns, converting them into essential data such as blood pressure, heart rate, and the presence of alcohol or cannabis. Currently, it covers about 18 different parameters with an accuracy rate of over 90 percent.

Global Impact

Predictmedix AI has deployed its AI scanner in hospitals in India and Indonesia, with major sporting events in the U.S. also benefiting from this technology. The focus is on regions where a high patient flow necessitates swift vital sign measurements. The data collected is anonymized and used to train the algorithm, ensuring privacy and data security.

Affordable Accessibility

The business model for this AI scanner is a lease model. For a monthly fee of $2,000 to $4,000, users can have unlimited access to the technology. This affordability, coupled with its high accuracy, makes it an attractive option for healthcare providers and employers alike.

Augmenting, Not Replacing

The AI scanner isn’t meant to replace the human triage process but rather augment it. When it comes to measuring impairment, it provides valuable information. For vital sign measurements, its accuracy levels can potentially replace the entire process of manually measuring vitals.

As healthcare technology continues to evolve, innovations like Predictmedix AI’s AI scanner are leading the way towards more efficient, secure, and patient-centric care. This technology has the potential to redefine healthcare practices on a global scale, ultimately benefiting both patients and healthcare providers.



Visit $PMED 5 Minute Research Profile On AGORACOM:

Visit $PMED Official Verified Discussion Forum On AGORACOM:

Watch $PMED Videos On AGORACOM YouTube Channel:



This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”) is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on, its related websites (;; and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.



This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit

Tags: , , , ,

Comments are closed.